Generic Twirla Availability
Last updated on Sep 10, 2026.
Twirla is a brand name of ethinyl estradiol/levonorgestrel, approved by the FDA in the following formulation:
| Manufacturer | Approval date | Strengths [RLD] |
|---|---|---|
| AGILE | February 14, 2020 |
|
Has a generic version of Twirla been approved?
No, the FDA has not approved a generic version of Twirla.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Twirla. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patent protection
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development. These patents may include claims related to the drug's formulation, manufacturing process, or other aspects.
| Patent Title | Dermal delivery device with reduced loss of its volatile components |
|---|---|
| Patent Number | 8,246,978 |
| Issue Date | August 21, 2012 |
| Inventor | Kydonieus Agis & Conway Robert G. & Rossi Thomas M. |
| Current Assignee | Agile Therapeutics, Inc. |
| Patent Description |
This invention relates to a transdermal drug delivery device that comprises an active ingredient (AI) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the...
This invention relates to a transdermal drug delivery device that comprises an active ingredient (AI) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the AI layer having a perimeter that extends beyond the perimeter of the AI layer in all directions, and an overlay comprising a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the AI layer having a perimeter of which extends beyond the perimeter of the AI layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the perimeter of the AI layer to form a seal that reduces or prevents volatile component loss.
|
| Patent Expiry Dates |
August 26, 2028
Drug Product: Yes |
| Patent Title | Dermal delivery device with in situ seal |
|---|---|
| Patent Number | 8,747,888 |
| Issue Date | June 10, 2014 |
| Inventor | Kydonieus Agis & Conway Robert G. & Rossi Thomas M. |
| Current Assignee | Agile Therapeutics, Inc. |
| Patent Description |
This invention relates to a transdermal drug delivery device that comprises an active ingredient (AI) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the...
This invention relates to a transdermal drug delivery device that comprises an active ingredient (AI) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the AI layer having a perimeter that extends beyond the perimeter of the AI layer in all directions, and an overlay comprising a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the Al layer having a perimeter of which extends beyond the perimeter of the AI layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the perimeter of the AI layer to form a seal that reduces or prevents volatile component loss.
|
| Patent Expiry Dates |
July 10, 2028
Drug Product: Yes |
| Patent Title | Dermal delivery device |
|---|---|
| Patent Number | 9,050,348 |
| Issue Date | June 9, 2015 |
| Inventor | Kydonieus Agis & Conway Robert G. & Rossi Thomas M. |
| Current Assignee | Agile Therapeutics, Inc. |
| Patent Description |
A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of...
A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%.
|
| Patent Expiry Dates |
July 10, 2028
Drug Product: Yes |
More about Twirla (ethinyl estradiol / levonorgestrel)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: contraceptives
- En español
Patient resources
Other brands
Aviane, Lessina, Seasonique, Alesse, ... +22 more
Professional resources
Other brands
Vienva, Aviane, Lessina, Seasonique, ... +50 more
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
